ArticleFrontiers in oncology2025
Application of propensity score matching in prognostic analysis of portal hypertension in hepatocellular carcinoma patients.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of portal hypertension on surgical prognosis after hepatectomy for hepatocellular carcinoma and assess the therapeutic value of concomitant splenic modulation procedures. Methods: We retrospectively analyzed HCC patients who underwent open hepatectomy with intraoperative portal venous pressure (PVP) measurement at our center between January 2013 and January 2020. Portal hypertension (PHT) was defined as PVP ≥ 25 cm H Results: Post-PSM analysis (59 matched pairs) revealed worse short-term outcomes in the PHT group: shorter surgical duration (p < 0.05) but greater intraoperative blood loss (anatomical/extensive hepatectomy subgroups, p < 0.01), higher postoperative bilirubin levels (p < 0.05), and longer hospital stay (non-anatomical/non-extensive hepatectomy subgroups, p < 0.01). Long-term OS and RFS showed no differences between groups pre- or post-PSM (p > 0.05). However, subgroup analyses demonstrated superior RFS in non-PHT patients undergoing non-anatomical and non-extensive hepatectomy (p = 0.035/0.034). Notably, pre-PSM data indicated improved RFS and OS in PHT patients receiving concomitant splenectomy or splenic artery ligation versus hepatectomy alone (p < 0.001). Conclusion: Compared with non-PHT patients, PHT was not associated with additional risk factors for poor prognosis after surgery. However, PHT may represent a significant risk indicator for recurrence in HCC patients undergoing non-anatomical or non-extensive hepatectomy. Furthermore, for HCC patients with concomitant PHT, hepatectomy combined with splenic artery ligation or splenectomy was associated with better long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.